Trial result ·
Ianalumab for the Treatment of Patients with Sjögren's Disease.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
Sjögren's disease is a complex autoimmune disease. No targeted drug is approved for it yet. Ianalumab is an antibody that lowers B cells and blocks their activation. This paper reports the NEPTUNUS-1 and NEPTUNUS-2 trials. They were 52-week, double-blind trials with a placebo group. In NEPTUNUS-1, patients got ianalumab 300 mg monthly or placebo. In NEPTUNUS-2, they got ianalumab monthly, every 3 months, or placebo. The main goal was the change in ESSDAI at week 48. Higher ESSDAI scores mean more disease activity.
What they found
NEPTUNUS-1 had 275 patients and NEPTUNUS-2 had 504. Monthly ianalumab cut ESSDAI clearly more than placebo at week 48 in both trials. The gap was -1.3 points in NEPTUNUS-1 and -1.0 points in NEPTUNUS-2. In both, the range of likely values reached 0.0. ESSDAI response and symptom scores did not differ clearly at week 48. Serious adverse events were similar with ianalumab and placebo. Nonserious reactions at or after the injection were more common with ianalumab.
What it means for patients
The authors say monthly ianalumab cut disease activity more than placebo at week 48. They also say ESSDAI response and symptom scores showed no clear gaps.
Why it is not certain yet
The ranges reached 0.0 in both trials. The p values were 0.0496 and 0.04, close to the cutoff. ESSDAI response and symptom scores did not differ clearly. The trials were funded by Novartis Pharma.
The registered trials
The paper names these trials from a public trial registry. Each trial page shows who the trial is for, its sites and its status.
Source
Ianalumab for the Treatment of Patients with Sjögren's Disease.
PubMed · PMID 42906087We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Sjögren's disease publications